Loading...
Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic society
Crona, J. Lee, Rebecca Sobczuk, P. Wysoki, O. Devnani, B. Prasongsook, N. Scheffler, M. Jalving, M.
Crona, J.
Lee, Rebecca
Sobczuk, P.
Wysoki, O.
Devnani, B.
Prasongsook, N.
Scheffler, M.
Jalving, M.
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Files
Keywords
Type
Other
Citation
Crona J, Lee R, Sobczuk P, Wysoki O, Devnani B, Prasongsook N, et al. Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic society. ESMO open. 2024 May;9(5):102531. PubMed PMID: 38796283. Pubmed Central PMCID: PMC11145755 Fabre, AstraZeneca, Chromition. PS has received travel grants from MSD, Roche, Novartis and Pierre Fabre, honoraria for lectures from Swixx BioPharma, Sandoz and BMS and advisory board honoraria from Sandoz. BD was an invited speaker for the Sabah Rectal Cancer Society, Malaysia. NP has received speaker/advisory board fees from Roche (Thailand), AstraZeneca, Novartis, Bristol Myers Squibb, Pfizer, Amgen. MS has received funding from Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Novartis, Pfizer, Roche, Sanofi-Aventis, Siemens Healthineers and Takeda, institutional research support from Amgen, BMS, Dracen Pharmaceuticals, Janssen, Novartis, Siemens Healthineers and Takeda, travel support from AstraZeneca, Boehringer Ingelheim, Janssen, Pfizer. MJ has received advisory board fees from BMS, Pierre Fabre, Merck, all paid to institution. All other authors have declared no conflicts of interest. Epub 2024/05/26. eng.